Biodesix to Acquire Oncimmune in the United States
Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.
254 Results
Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.
Biodesix will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy
Biodesix has entered into an agreement with Thermo Fisher Scientific.
Biodesix presented new data showing that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer treated with immune checkpoint inhibitors